Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00088790 | AZD5438 in Patients With Advanced Solid Malignancies | PHASE1 | COMPLETED | - | — | — | Jul 1, 2004 | Dec 1, 2005 | Jan 26, 2011 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| AZD5438 | DRUG | - |
Inclusion Criteria: * Advanced solid malignancy * Cancer refractory to standard treatments or for which no standard therapy exits Exclusion Criteria: * Radiotherapy within 3 weeks of the start of treatment * Investigational product within the last 3 weeks * Systemic cytotoxic anti-cancer therapy ...